文献速递肝病消化道肿瘤与早癌

18F-氟胆碱正电子发射断层显像/计算机断层显像可改善肝细胞癌患者的肿瘤分期与治疗分配

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2018-03-06

研究评估双示踪剂18F-氟胆碱与18F-氟脱氧葡萄糖PET/CT对肝细胞癌分期和治疗分配的影响。在177例患者共192次双示踪剂PET/CT扫描中,基于双示踪剂PET/CT,26例(21%)检出新的病灶,14例(11%)BCLC分期升级,17例(14%)治疗策略改变。在甲胎蛋白不明原因升高、常规影像可疑病灶及无活动性肝癌等待肝移植的患者中,双示踪剂PET/CT也改变了部分患者的最终治疗。

要点

  • 双示踪剂PET/CT在26例(21%)肝细胞癌患者中检出新的病灶。
  • 双示踪剂PET/CT使14例(11%)患者BCLC分期升级、17例(14%)患者治疗策略改变。
  • 在甲胎蛋白不明原因升高和常规影像可疑病灶的患者中,双示踪剂PET/CT分别改变4/9(44%)和10/25(40%)患者的最终治疗。

核心结论

  • 用于肝细胞癌分期时,双示踪剂PET/CT分别使11%和14%的患者实现BCLC分期升级和治疗方案修改。
  • 双示踪剂PET/CT在特定情况下(甲胎蛋白不明原因升高、可疑病灶或无活动性肝癌的移植前评估)可能也有用。

研究设计与样本

  • 回顾性研究,共纳入177例肝细胞癌患者,进行192次双示踪剂(18F-氟胆碱和18F-氟脱氧葡萄糖)PET/CT扫描。
  • 基于常规影像回顾性收集BCLC分期和治疗建议,以及双示踪剂PET/CT检出的新病灶和基于双示踪剂PET/CT的BCLC分类或治疗分配变化。

主要发现

  • 患者主要为男性(87.5%),伴有肝硬化(71%),病因为酒精±非酒精性脂肪性肝炎(26%)、病毒感染(62%)或不明原因(12%)。
  • 在122例因分期行PET/CT的患者中,基于常规影像的BCLC分期为0/A期61例(50%)、B期32例(26%)、C期29例(24%)。
  • 双示踪剂PET/CT在26例(21%)患者中检出新病灶,使14例(11%)患者BCLC分期升级,并改变17例(14%)患者的治疗策略。
  • 双示踪剂PET/CT改变了甲胎蛋白不明原因升高的4/9(44%)患者、常规影像可疑病灶的10/25(40%)患者以及桥接治疗后肿瘤缓解但无活动性肝癌等待肝移植的3/36(8%)患者的最终治疗。

临床怎么用

  • 作者结论认为,用于肝细胞癌分期时,双示踪剂PET/CT可使部分患者BCLC分期升级并修改治疗方案。
  • 作者认为双示踪剂PET/CT在甲胎蛋白不明原因升高、可疑病灶或无活动性肝癌的移植前评估等特定情况下可能也有用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) staging according to the Barcelona Clinical Liver Cancer (BCLC) classification is based on conventional imaging. The aim of our study was to assess the impact of dual-tracer 18F-fluorocholine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) on tumor staging and treatment allocation. METHODS: A total of 192 dual-tracer PET/CT scans (18F-fluorocholine and 18F-fluorodeoxyglucose PET/CT) were performed in 177 patients with HCC. BCLC staging and treatment proposal were retrospectively collected based on conventional imaging, along with any new lesions detected, and changes in BCLC classification or treatment allocation based on dual-tracer PET/CT. RESULTS: Patients were primarily men (87.5%) with cirrhosis (71%) due to alcohol ± non-alcoholic steatohepatitis (26%), viral infection (62%) or unknown causes (12%). Among 122 patients with PET/CT performed for staging, BCLC stage based on conventional imaging was 0/A in 61 patients (50%), B in 32 patients (26%) and C in 29 patients (24%). Dual-tracer PET/CT detected new lesions in 26 patients (21%), upgraded BCLC staging in 14 (11%) and modified treatment strategy in 17 (14%). In addition, dual-tracer PET/CT modified the final treatment in 4/9 (44%) patients with unexplained elevation of alpha-fetoprotein (AFP), 10/25 patients (40%) with doubtful lesions on conventional imaging and 3/36 patients (8%) waiting for liver transplantation without active HCC after tumor response following bridging therapy. CONCLUSION: When used for HCC staging, dual-tracer PET/CT enabled BCLC upgrading and treatment modification in 11% and 14% of patients, respectively. Dual-tracer PET/CT might also be useful in specific situations (an unexplained rise in AFP, doubtful lesions or pre-transplant evaluation of patients without active HCC). LAY SUMMARY: Using a combination of tracers 18F-fluorocholine and 18F-fluorodeoxyglucose when performing positron emission tomography/computed tomography (PET/CT), often called a PET scan, helps to identify new tumor lesions in patients with hepatocellular carcinoma. This technique enabled staging modification of patients' tumors and led to changes in treatment allocation in certain patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chalaye J, Costentin CE, Luciani A, et al. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. J Hepatol. 2018. PMID: 29518452. doi:10.1016/j.jhep.2018.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。